ReviewThe pharmacogenomics journal2008
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
Review in The pharmacogenomics journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Clinical pharmacology and therapeutics · 2012Guideline
- Cost effectiveness of pharmacogenomics: a critical and systematic review.PharmacoEconomics · 2010Pooled it
- Genomics in Health and Biomedicine.Advances in experimental medicine and biology · 2026Review
- A Comprehensive Review ofPharmaceuticals (Basel, Switzerland) · 2021Review
- Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder.The pharmacogenomics journal · 2021Review
- Genetic Testing in Clinical Settings.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.The pharmacogenomics journal · 2015Review
- Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2015Article
- Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Journal of personalized medicine · 2013Review
- Systematic reviews of animal models: methodology versus epistemology.International journal of medical sciences · 2013Review
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.ISRN pharmacology · 2013Article
- Personalized medicine: is it a pharmacogenetic mirage?British journal of clinical pharmacology · 2012Review
- Pharmacogenomics and individualized medicine: translating science into practice.Clinical pharmacology and therapeutics · 2012Article
- Animal models and conserved processes.Theoretical biology & medical modelling · 2012Article
- The Nuremberg Code subverts human health and safety by requiring animal modeling.BMC medical ethics · 2012Review
- The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.Pharmacogenomics and personalized medicine · 2012Article
- Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.Advances in virology · 2012Article
- HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.International journal of hepatology · 2012Article
- HLA-B*5701 testing to predict abacavir hypersensitivity.PLoS currents · 2010Article
- Successes achieved and challenges ahead in translating biomarkers into clinical applications.The AAPS journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypersensitivity (HSR) to abacavir (ABC) pharmacogenetics (PGx) program represents the progression from an exploratory discovery to a validated biomarker. Within the program, two retrospective PGx studies were conducted to identify HIV-1 patients at increased risk for ABC HSR, a treatment-limiting and potentially life-threatening adverse event. A strong statistical association between the major histocompatibility complex allele, HLA-B*5701, and clinically diagnosed ABC HSR was identified but varied between racial populations. Subsequently, ABC skin patch testing was introduced as a research tool to supplement clinical case ascertainment. In a randomized, prospective study evaluating the clinical utility of HLA-B*5701 screening, avoidance of ABC in HLA-B*5701-positive patients significantly reduced clinically diagnosed ABC HSR and eliminated patch test-positive ABC HSR. Finally, a retrospective PGx study supports the generalizability of the association across races. Prospective HLA-B*5701 screening should greatly reduce the incidence of ABC HSR by identifying patients at high risk for ABC HSR before they are treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.